Ziopharm Oncology to Report Third Quarter Financial Results on November 8, 2021

Rhea-AI Summary

Ziopharm Oncology, Inc. (Nasdaq: ZIOP) will report its third-quarter financial results for 2021 on November 8, 2021, after U.S. market close. A conference call and webcast will follow at 4:30 p.m. ET to discuss the results and provide a corporate update. Investors can access the call by dialing the provided numbers or through a live webcast available on the company’s website. Ziopharm focuses on developing innovative T-cell receptor therapies using its proprietary Sleeping Beauty gene transfer platform and collaborates with leading cancer research institutions.

Positive

• Focus on innovative T-cell receptor therapies.
• Collaborations with National Cancer Institute and MD Anderson Cancer Center.

Negative

• None.

HOUSTON, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced that it will report financial results for the third quarter ended September 30, 2021 on Monday, November 8, 2021, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 4:30 p.m. ET to provide a corporate update and review the financial results.

The conference call can be accessed by dialing 877-451-6152 (United States) or 201-389-0879 (International) with the conference code 13724384. A live webcast may be accessed using the link here, or by visiting the “Investors” section of the Ziopharm website at www.ziopharm.com. After the live webcast, the event will be archived on Ziopharm’s website for approximately 90 days after the call.

About Ziopharm Oncology, Inc.
Ziopharm is a clinical-stage oncology-focused cell therapy company, developing T-cell receptor (TCR) therapies based on its non-viral Sleeping Beauty gene transfer platform and its unique cancer hotspot Library, covering common tumor-related mutations in key oncolytic genes such as KRAS and TP53. The Company has clinical and strategic collaborations with the National Cancer Institute and The University of Texas MD Anderson Cancer Center. For more information, please visit www.ziopharm.com.

Investor Relations Contact:
Alex Lobo
Stern Investor Relations
Alex.lobo@sternir.com

FAQ

When will Ziopharm report its third-quarter financial results?

Ziopharm will report its third-quarter financial results on November 8, 2021, after the close of U.S. markets.

What time is the Ziopharm conference call for the third-quarter results?

The conference call will take place at 4:30 p.m. ET on November 8, 2021.

How can I access the Ziopharm conference call?

You can access the conference call by dialing 877-451-6152 (U.S.) or 201-389-0879 (International) with the conference code 13724384, or through a live webcast on their website.

What is Ziopharm's focus in oncology?

Ziopharm is focused on developing T-cell receptor therapies based on its non-viral Sleeping Beauty gene transfer platform.